REVIEW ON LIQUISOLID COMPACTS

The “Liquid-solid” strategy is a cutting-edge and effective addition to such objectives for boosting solubility and dissolving, and so increasing bioavailability. This tactic can improve the rate of solubility and bioavailability of BCS class-II medications. Approximately 40–50% of drugs available are not soluble in water. Since liquid solid compact technology is the best alternative, industry must overcome a challenge by making unit dose forms more soluble. The Liquisolid system combines the Orodispersible and Liquisoild methodologies. Utilising Liquisolid compact technology for oral drug delivery is an innovative strategy. The first to discuss liquidsolid compact technology was “Spireas et al” in 1998. It is possible to transform acceptable nonvolatile liquid carriers, such as solutions or suspensions of water-insoluble medications, into flowable and compressible powders using the novel formulation process of liqui-solid compacts. Improving the oral bioavailability of poorly water-soluble drugs is one of the trickiest aspects of drug research. Using a more modern technique called as “powdered solution technology” or “Liquisolid technology,” water-insoluble medications have been transformed into rapid-release solid dose forms.The industry has a challenging obstacle in the development of the ideal solid dosage form unit: drug solubility. In order to create powders that flow and compress properly, the procedure entails dissolving the insoluble drug in a nonvolatile solvent and mixing drug-loaded solutions with the right carrier and coating materials.